Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Other Stockholders Equity
Equity items not reported separately, such as additional paid-in capital or treasury stock.
Actuate Therapeutics IncNASDAQ: ACTU
Other Stockholders Equity · Q1 FY2026 · quarter ended Mar 2026
Other stockholders equity remains negative
Q1 FY2026 other stockholders equity was $0, compared with $0 a year earlier.
Context
- Other stockholders equity amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other stockholders equity increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Stockholders Equity history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- +100.0%
| Period | Period end | Other Stockholders Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | +100.0% |
| FY2024 | 2024-12-31 | (834) | -83500.0% |
| FY2023 | 2023-12-31 | 1 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Stockholders Equity vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so other stockholders equity is compared through growth and share of total assets rather than absolute size.
- Other stockholders equity amounts to 0.0% of total assets for ACTU, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACTU) | — | — | — | 0.0% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.